How many stocks are there of Biotest?
The current number of stocks of Biotest is 39.57 M undefined.
Biotest Stocks 2024
Biotest Stocks
39.57 M
Ticker
BIO.DE
ISIN
DE0005227201
WKN
522720
In 2024, Biotest had 39.57 M outstanding stocks, a 0% change from the 39.57 M stocks in the previous year.
The Biotest Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2026e | 39.57 |
| 2025e | 39.57 |
| 2024e | 39.57 |
| 2023 | 39.57 |
| 2022 | 39.57 |
| 2021 | 39.57 |
| 2020 | 39.57 |
| 2019 | 39.57 |
| 2018 | 39.57 |
| 2017 | 39.57 |
| 2016 | 39.57 |
| 2015 | 39.57 |
| 2014 | 39.57 |
| 2013 | 37.4 |
| 2012 | 35.2 |
| 2011 | 35.2 |
| 2010 | 35.2 |
| 2009 | 35.2 |
| 2008 | 35.2 |
| 2007 | 32.8 |
| 2006 | 32 |
| 2005 | 26.3 |
| 2004 | 24.9 |
Biotest shares outstanding DE0005227201 · 522720
The number of shares was Biotest in 2023 — This indicates how many shares 39.571 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Biotest earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Biotest's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Biotest’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biotest's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2004 | 24.9 M Aktien |
| 2005 | 26.3 M Aktien |
| 2006 | 32 M Aktien |
| 2007 | 32.8 M Aktien |
| 2008 | 35.2 M Aktien |
| 2009 | 35.2 M Aktien |
| 2010 | 35.2 M Aktien |
| 2011 | 35.2 M Aktien |
| 2012 | 35.2 M Aktien |
| 2013 | 37.4 M Aktien |
| 2014 | 39.57 M Aktien |
| 2015 | 39.57 M Aktien |
| 2016 | 39.57 M Aktien |
| 2017 | 39.57 M Aktien |
| 2018 | 39.57 M Aktien |
| 2019 | 39.57 M Aktien |
| 2020 | 39.57 M Aktien |
| 2021 | 39.57 M Aktien |
| 2022 | 39.57 M Aktien |
| 2023 | 39.57 M Aktien |
| 2024e | 39.57 M Aktien |
| 2025e | 39.57 M Aktien |
| 2026e | 39.57 M Aktien |
Biotest Aktienanalyse
What does Biotest do?
Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Biotest's Shares Outstanding
Biotest's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Biotest’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Biotest’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Biotest’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Biotest stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Biotest are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Biotest evolved in recent years?
The number of shares of Biotest has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Biotest as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Biotest?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Biotest pay?
Over the past 12 months, Biotest paid a dividend of 0.05 EUR . This corresponds to a dividend yield of about 0.12 %. For the coming 12 months, Biotest is expected to pay a dividend of 0.44 EUR.
What is the dividend yield of Biotest?
The current dividend yield of Biotest is 0.12 %.
When does Biotest pay dividends?
Biotest pays a quarterly dividend. This is distributed in the months of June, June, June, September.
How secure is the dividend of Biotest?
Biotest paid dividends every year for the past 2 years.
What is the dividend of Biotest?
For the upcoming 12 months, dividends amounting to 0.44 EUR are expected. This corresponds to a dividend yield of 1.07 %.
In which sector is Biotest located?
Biotest is assigned to the 'Health' sector.
Wann musste ich die Aktien von Biotest kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Biotest from 9/4/2017 amounting to 0.05 EUR, you needed to have the stock in your portfolio before the ex-date on 8/31/2017.
When did Biotest pay the last dividend?
The last dividend was paid out on 9/4/2017.
What was the dividend of Biotest in the year 2023?
In the year 2023, Biotest distributed 0 EUR as dividends.
In which currency does Biotest pay out the dividend?
The dividends of Biotest are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Biotest
Our stock analysis for Biotest Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotest Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
